Questions

1. Clinical Diagnosis:
   • Attention-Deficit / Hyperactivity Disorder (ADHD), Combined Presentation (DSM-5 code 314.01).
2. Standardized Assessment Tools:
   • International Scales: Vanderbilt ADHD Diagnostic Rating Scale (VADRS); Conners Comprehensive Behavior Rating Scales (Conners CBRS) / Conners-3; Child Behavior Checklist (CBCL).
   • Validated Indian Tool: INCLEN Diagnostic Tool for ADHD (INDT-ADHD).
3. Medical Conditions to Exclude:
   • Neurosensory deficits (undiagnosed hearing loss or refractive visual errors).
   • Specific Learning Disorder (SLD) or intellectual disability masquerading as poor classroom task engagement.
   • Pediatric sleep disorders (obstructive sleep apnea causing daytime behavioral disinhibition).
   • Endocrine/metabolic disorders (hyperthyroidism) or absence seizures (epilepsy presenting with brief inattention episodes).
4. Multimodal Management Plan:
   • Behavioral Interventions: Parent Child Interaction Therapy (PCIT) / Behavioral Parent Training (BPT), classroom behavioral modifications (preferential front-row seating, visual schedules, chunked instructions, token economy systems).
   • First-Line Pharmacotherapy: Methylphenidate hydrochloride (immediate-release formulation).
     • Starting dose: $0.2 \text{ to } 0.3\text{ mg/kg/dose}$ orally once or twice daily (administered after breakfast and lunch; avoiding late evening doses to prevent insomnia).
     • Titration: Increase by $0.1 \text{ to } 0.2\text{ mg/kg/day}$ weekly based on classroom/home response up to a maximum of $1.0\text{ mg/kg/day}$ (or maximum $60\text{ mg/day}$).
   • Pre-treatment & Ongoing Monitoring: Baseline height, weight, body mass index (plotted on growth charts to monitor appetite suppression), resting heart rate, blood pressure, personal/family history of sudden unexplained cardiac death or structural heart disease, and screening for motor/vocal tics.

1. Psychiatric Diagnosis & Duration:
   • Major Depressive Disorder (MDD), severe single episode without psychotic features.
   • Required Duration: Symptoms must be persistently present nearly every day for a minimum of 2 consecutive weeks (representing a definite change from previous functioning, including depressed/irritable mood or loss of interest/pleasure).
2. Organic/Medical Differential Diagnoses:
   • Primary hypothyroidism (screen with serum TSH and free T4).
   • Autoimmune/inflammatory encephalitis or systemic lupus erythematosus (SLE cerebritis).
   • Wilson disease (hepatolenticular degeneration presenting with behavioral changes).
   • Intracranial space-occupying lesion (frontal lobe tumor) or chronic occult central nervous system infection.
   • Chronic severe nutritional deficiencies (vitamin B12, folate, or severe iron deficiency anemia).
3. HEEADSSS Interview Framework:
   • H: Home environment (family dynamics, relationships, living situation).
   • E: Education / Employment (academic trajectory, attendance, vocational goals).
   • E: Eating / Exercise (dietary patterns, body image, weight fluctuations).
   • A: Activities (peer friendships, sports, leisure pursuits, screen time).
   • D: Drugs / Alcohol (substance experimentation, tobacco, alcohol, vaping).
   • S: Sexuality / Gender identity (sexual activity, contraception, identity exploration).
   • S: Suicide / Depression (hopelessness, self-harm, suicidal ideation, intent, plan).
   • S: Safety (bullying, domestic violence, exposure to weapons, high-risk behaviors).
4. Pharmacotherapy Protocol & Safety:
   • First-line Drug of Choice: Fluoxetine (Selective Serotonin Reuptake Inhibitor, US-FDA approved for depression in children $\ge 8\text{ years}$) or Escitalopram (approved for adolescents $\ge 12\text{ years}$).
   • Fluoxetine Dosing:
     • Initial starting dose: $10\text{ mg}$ orally once daily in the morning.
     • Titration: Increase after 2 to 3 weeks to $20\text{ mg}$ daily based on clinical response and tolerability (maximum adolescent dose: $40\text{ to } 60\text{ mg/day}$).
   • Maintenance Duration: Continue treatment for at least 6 to 12 months following complete symptom remission to prevent clinical relapse.
   • Boxed Warning (Black-Box Warning): US-FDA warning regarding increased risk of treatment-emergent suicidal ideation, suicide attempts, and paradoxical agitation/hostility during the initial 4 to 8 weeks of SSRI therapy or dose titration. Close weekly monitoring is mandatory during early treatment.

1. Baseline Laboratory Screening (Any 6):
   • Complete blood count (CBC) with peripheral blood smear (screening for nutritional anemias, hemoglobinopathies, and occult infection).
   • Serum ferritin and iron profile (screening for latent iron deficiency).
   • Serum electrolytes, blood urea nitrogen, and serum creatinine.
   • Liver function tests (total and direct bilirubin, AST, ALT, alkaline phosphatase, total protein, serum albumin).
   • Venous blood lead level (BLL) (high risk of environmental lead exposure in institutional/older facilities).
   • Serum 25-hydroxyvitamin D and calcium, phosphorus, alkaline phosphatase (evaluation for occult nutritional rickets).
   • Urinalysis (routine microscopy and chemical analysis).
2. Infectious Disease Screening Panel:
   • Hepatitis B: Hepatitis B surface antigen (HBsAg), anti-HBs antibody, and anti-HBc total antibody.
   • Hepatitis C: Anti-HCV antibody (with reflex HCV RNA PCR if reactive).
   • Human Immunodeficiency Virus: 4th-generation HIV-1/2 antigen/antibody combination immunoassay.
   • Syphilis: Rapid Plasma Reagin (RPR) or VDRL test, confirmed by Treponema pallidum particle agglutination (TP-PA) if positive.
   • Tuberculosis Screening: Mantoux tuberculin skin test (TST, $\ge 10\text{ mm}$ considered positive regardless of prior BCG status) or Interferon-Gamma Release Assay (IGRA).
   • Gastrointestinal Parasites: Stool microscopy for ova, cysts, and parasites (3 consecutive stool specimens) and Giardia lamblia stool antigen.
3. Catch-Up Immunization Strategy (Zero Records Available):
   • Regard the child as completely unvaccinated and initiate an accelerated catch-up schedule according to the Indian Academy of Pediatrics (IAP) / WHO guidelines.
   • Visit 1 (Immediate / Day 0): DTwP/DTaP (dose 1), Inactivated Polio Vaccine (IPV dose 1), Hib (dose 1), Hepatitis B (dose 1), MMR (dose 1), Pneumococcal Conjugate Vaccine (PCV dose 1), Varicella (dose 1), Hepatitis A (single-dose live attenuated or dose 1 inactivated).
   • Subsequent schedule:
     • Minimum 4 weeks after Visit 1: DTwP/DTaP (dose 2), IPV (dose 2), Hepatitis B (dose 2).
     • Minimum 4 weeks after Visit 2: DTwP/DTaP (dose 3), IPV (dose 3), MMR (dose 2).
     • Minimum 6 months after Visit 1: Hepatitis B (dose 3), Varicella (dose 2), Hepatitis A (dose 2 if using inactivated vaccine).
     • Annual Influenza vaccine.
4. Developmental and Behavioral Guidance for Parents:
   • Attachment Building (Indiscriminate Friendliness vs. Withdrawal): Practice exclusive caregiving by the two primary adoptive parents during the initial 3 to 6 months; avoid large welcoming parties, rotating external babysitters, or multiple handling by extended family to help the child learn that her needs are met reliably by specific primary caregivers.
   • Feeding and Food Hoarding Behaviors: Institutionalized children may exhibit food gorging, rapid swallowing without chewing, or hiding food in their rooms due to past rationing. Parents should provide predictable, structured meals without forced feeding, offer reassurance of food abundance, and never use food deprivation as discipline.
   • Sleep Transitions: Expect nighttime waking, rocking behaviors, or head-banging (common institutional self-soothing stereotypic habits). Provide transitional objects, dim night lights, consistent bedtime routines, and parental co-presence until the child settles.
   • Sensory and Emotional Dysregulation: The sudden shift from a regimented institutional setting to an unpredictable home environment can cause sensory overload or frequent emotional meltdowns. Implement predictable daily routines, structured transitions, and calm responsive parenting without harsh punitive measures.

1. Definitive Diagnosis & Subtype:
   • Anorexia Nervosa (DSM-5), Restricting Subtype (Extreme severity based on BMI $< 13\text{ kg/m}^2$).
2. Anthropometric Calculations:
   $$ > \begin{aligned} > \text{Current BMI} &= \frac{\text{Weight (kg)}}{[\text{Height (m)}]^2} \\ > &= \frac{26.0}{(1.48)^2} = \frac{26.0}{2.1904} \\ > &= \mathbf{11.87\text{ kg/m}^2} \quad (\text{Extreme thinness, } Z\text{-score} < -3\text{ SD}) > \end{aligned} > $$
   • Median BMI for a 12-year-old girl is approximately $18.0\text{ kg/m}^2$.
     $$ > \begin{aligned} > \%\text{ of Median BMI} &= \frac{11.87}{18.0} \times 100 = \mathbf{65.9\%} \quad (< 70\%\text{ indicates severe life-threatening malnutrition}) > \end{aligned} > $$
3. Emergency Inpatient Admission Criteria (Any 4):
   • Severe bradycardia: Resting heart rate $< 50\text{ beats/min}$ (patient is 42 bpm).
   • Severe hypotension: Systolic blood pressure $< 80\text{ mmHg}$ or diastolic $< 50\text{ mmHg}$ (patient is 78/48 mmHg).
   • Significant hypothermia: Core body temperature $< 35.5^\circ\text{C}$ (patient is 35.4°C).
   • Weight $< 75\%$ of median BMI for age/sex (patient is 65.9%).
   • Cardiac dysrhythmias or prolonged QTc interval ($> 460\text{ ms}$) on 12-lead ECG.
   • Acute severe electrolyte disturbances (hypokalemia, hypophosphatemia, hypomagnesemia).
4. Refeeding Rehabilitation Protocol:
   • Initial Caloric Intake: Begin cautiously at $30 \text{ to } 40\text{ kcal/kg/day}$ (approximately $800 \text{ to } 1000\text{ kcal/day}$ for this 26 kg child) divided into 3 small balanced meals and 3 snacks or continuous/bolus nasogastric feeds.
   • Caloric Advancement: Increase gradually by $150 \text{ to } 200\text{ kcal/day}$ every 2 to 3 days with target weight gain of $0.5 \text{ to } 1.0\text{ kg/week}$ in inpatient settings.
   • Prophylaxis: Administer oral Thiamine ($100\text{ mg/day}$) and a multivitamin supplement prior to initiating carbohydrates to prevent Wernicke encephalopathy.
   • Daily Biochemical Monitoring: Serum inorganic phosphorus (hallmark of refeeding syndrome is severe hypophosphatemia), potassium, magnesium, calcium, glucose, and daily 12-lead ECG monitoring for QTc prolongation.

1. Paradoxical Video Game Attention (Hyperfocus / Incentive Salience):
   • ADHD is not a complete inability to pay attention, but rather a disorder of attention regulation and executive control mediated by hypoactivation in prefrontal-striatal dopaminergic networks.
   • Video games and dynamic digital screens provide continuous, instantaneous, novel visual-auditory stimuli and micro-rewards (immediate dopamine release), bypassing the deficient endogenous self-directed motivational systems.
   • In contrast, low-stimulation tasks (such as classroom listening or independent chores) require internally generated sustained focus, executive effort, and delayed gratification, which fail to generate adequate prefrontal dopaminergic signaling.
2. DSM-5 Diagnostic Requirements:
   • Symptom Count: At least $\ge 6$ symptoms of inattention and/or $\ge 6$ symptoms of hyperactivity-impulsivity (for individuals $< 17\text{ years}$).
   • Duration: Persistently present for at least 6 consecutive months to a degree inconsistent with developmental level.
   • Age of Onset: Several symptoms must have been present prior to age 12 years.
   • Multi-setting Manifestation: Clear impairment must be evident in two or more settings (e.g., home, school/daycare, social settings).
3. First-Line Interventions for Preschoolers (4–5 Years):
   • Evidence-based Behavioral Parent Training (BPT) is the mandatory first-line therapy (e.g., Triple P [Positive Parenting Program], Parent-Child Interaction Therapy [PCIT], or Incredible Years).
   • Structured classroom behavioral management programs delivered by preschool teachers.
   • Pharmacotherapy is reserved exclusively as a second-line option when evidence-based behavioral therapies fail to provide substantial improvement and there is severe ongoing functional impairment or safety risk.
4. Pharmacotherapy in Children $\ge 6$ Years:
   • First-line Drug: Methylphenidate hydrochloride (Immediate-release formulation or extended-release formulation).
   • Starting Dose: $0.2 \text{ to } 0.3\text{ mg/kg/dose}$ orally once or twice daily (typically $5\text{ mg}$ once or twice daily after meals).
   • Titration & Maximum Dose: Titrate upwards by $5 \text{ to } 10\text{ mg/day}$ at weekly intervals based on efficacy and side-effect profile; maximum dose is $1.0\text{ mg/kg/day}$ or up to $60\text{ mg/day}$.
   • Common Adverse Effects: Anorexia/weight loss, sleep disturbances (insomnia), headache, abdominal pain, transient elevation of blood pressure and heart rate, growth deceleration, and emergence of motor/vocal tics.

flowchart TD
    A[Child 4-5 Years with Suspected ADHD] --> B[Obtain Multi-informant Rating Scales: Home & Preschool]
    B --> C[Confirm DSM-5 Criteria: >=6 Symptoms in >=2 Settings for >=6 Months]
    C --> D[First-Line Therapy: Behavioral Parent Training PCIT / Triple-P]
    D --> E{Adequate Clinical Improvement after 6 Months?}
    E -- Yes --> F[Continue Behavioral Strategies & Periodic Surveillance]
    E -- No --> G{Child Age >=6 Years & Severe Persistent Impairment?}
    G -- Yes --> H[Initiate Methylphenidate 0.2-0.3 mg/kg/dose + Maintain Behavioral Therapy]
    G -- No --> I[Intensify BPT + School Consultation; Defer Stimulants unless Extreme Safety Risk]

1. Primary Diagnosis:
   • Autism Spectrum Disorder (ASD).
2. Core DSM-5-TR Symptom Domains:
   • Domain A: Persistent deficits in social communication and social interaction across multiple contexts, manifest by all three of the following:
     • Deficits in social-emotional reciprocity (e.g., abnormal social approach, failure of normal back-and-forth conversation, reduced sharing of interests/emotions/affect).
     • Deficits in nonverbal communicative behaviors used for social interaction (e.g., poorly integrated verbal/nonverbal communication, abnormalities in eye contact and body language, lack of facial expressions and gestures).
     • Deficits in developing, maintaining, and understanding relationships (e.g., difficulties adjusting behavior to suit social contexts, difficulties in sharing imaginative play or making friends, absence of interest in peers).
   • Domain B: Restricted, repetitive patterns of behavior, interests, or activities, manifest by at least two of the following:
     • Stereotyped or repetitive motor movements, use of objects, or speech (e.g., simple motor stereotypies, lining up toys, echolalia, idiosyncratic phrases).
     • Insistence on sameness, inflexible adherence to routines, or ritualized patterns of verbal/nonverbal behavior (e.g., extreme distress at small changes, rigid greeting rituals, need to take same route).
     • Highly restricted, fixated interests that are abnormal in intensity or focus.
     • Hyper- or hyporeactivity to sensory input or unusual interest in sensory aspects of the environment (e.g., apparent indifference to pain/temperature, adverse response to specific sounds/textures, excessive smelling or touching of objects).
3. Screening Tools & Genetic Workup:
   • Screening Tools:
     • Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F).
     • Screening Tool for Autism in Toddlers and Young Children (STAT).
   • First-Line Genetic Investigations:
     • Chromosomal Microarray (CMA) / Array Comparative Genomic Hybridization (aCGH) to identify copy number variations (CNVs).
     • Fragile X DNA testing (FMR1 gene CGG repeat analysis).
     • Whole Exome Sequencing (WES) if CMA and Fragile X testing are unrevealing.
4. Prenatal & Perinatal Risk Factors:
   • Advanced parental age (maternal age ≥35 years and paternal age ≥40 years).
   • Short interpregnancy interval (<18–24 months).
   • Extreme prematurity (gestational age <32 weeks) and very low birth weight (<1500 g).
   • Prenatal exposure to antiepileptic drugs (notably sodium valproate) or maternal metabolic syndrome/gestational diabetes.
   • Maternal prenatal infections (e.g., Cytomegalovirus, Rubella).

graph TD
    A[Child with Social Communication Delay at 18-24 Mo] --> B[Formal Screening: M-CHAT-R/F]
    B -->|Medium/High Risk| C[Comprehensive Multidisciplinary Evaluation]
    C --> D[DSM-5-TR Diagnostic Formulation]
    D --> E[First-Line Genetic Testing: CMA + FMR1 PCR]
    D --> F[Early Intensive Behavioral Intervention: ABA / ESDM]
    D --> G[Speech & Occupational Sensory Therapy]

1. Distinction: Bereavement vs. Major Depressive Disorder:
   • Pervasiveness of Affect: In uncomplicated bereavement, dysphoria occurs in waves or pangs ("bursts of grief") triggered by reminders, with intermittent preservation of positive affect and humor. In MDD, depressed or irritable mood is persistent and pervasive across nearly all contexts for ≥2 weeks.
   • Cognitive Content & Self-Esteem: In bereavement, thoughts center on memories, yearning, and longing for the deceased, with self-esteem largely preserved. In MDD, cognition is dominated by self-loathing, pervasive feelings of worthlessness, morbid guilt, and irrational self-blame unrelated to the loss.
   • Ideation of Death: In bereavement, thoughts of dying are typically restricted to joining the deceased ("I miss him so much I wish I were with him"). In MDD, suicidal ideation stems from worthlessness, hopelessness, perceiving oneself as a burden, or an active desire to end one's life ("I do not deserve to live").
2. Diagnosis & Red-Flag Feature:
   • Diagnosis: Major Depressive Disorder (MDD), severe, single episode (triggered by parental bereavement).
   • Red-Flag Feature: Severe suicidal ideation and morbid guilt / death wish ("I am completely useless and wish I hadn't survived instead of him").
3. Psychiatric Comorbidities:
   • Generalized Anxiety Disorder (GAD) or Panic Disorder.
   • Substance Use Disorders (alcohol, cannabis, nicotine abuse).
   • Attention-Deficit/Hyperactivity Disorder (ADHD) or Conduct Disorder.
   • Persistent Complex Bereavement Disorder (prolonged grief disorder).
4. Management Plan:
   • Immediate Safety Assessment: Urgent formal suicide risk stratification; secure home environment (remove sharp objects, medications, firearms); establish a safety crisis contract.
   • Psychotherapy: Individual Cognitive Behavioral Therapy (CBT) or Interpersonal Psychotherapy for Adolescents (IPT-A).
   • Pharmacotherapy:
     • First-line agent: Fluoxetine (FDA-approved for pediatric depression ≥8 years).
     • Starting dose: 10 mg orally once daily in the morning; titrate after 2 to 4 weeks to 20 mg orally once daily based on clinical response and tolerability (maximum: 40–60 mg/day).
     • Monitor closely for treatment-emergent suicidality during the initial 4 to 8 weeks (black-box warning).

1. Specific Diagnosis:
   • Binge Eating Disorder (BED), moderate severity (defined as 4–7 binge eating episodes per week; DSM-5-TR requires ≥1 episode/week for ≥3 months).
2. Differential Diagnosis:
   • Bulimia Nervosa: Characterized by recurrent episodes of binge eating accompanied by inappropriate compensatory behaviors to prevent weight gain (self-induced vomiting, abuse of laxatives/diuretics/enemas, fasting, or driven excessive exercise). BED is defined by the absence of regular compensatory purging or non-purging behaviors.
   • Prader-Willi Syndrome: Characterized by hypothalamic insatiable hyperphagia without subjective loss-of-control distress or post-binge emotional guilt/remorse; accompanied by a history of infantile hypotonia with failure to thrive, short stature, hypogonadism, dysmorphic facial features (almond-shaped eyes, thin upper lip), cognitive impairment, and paternal deletion of 15q11-q13 (or maternal uniparental disomy).
3. Comorbidities:
   • Psychiatric: Major Depressive Disorder, Generalized Anxiety Disorder, Body Dysmorphic Disorder, Low self-esteem / social avoidance.
   • Metabolic/Physical: Type 2 Diabetes Mellitus / Insulin resistance, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Dyslipidemia, Obstructive Sleep Apnea (OSA), Idiopathic intracranial hypertension (pseudotumor cerebri).
4. Multimodal Management:
   • Psychotherapy (First-Line):
     • Cognitive Behavioral Therapy adapted for Eating Disorders (CBT-ED) targeting binge triggers, maladaptive food rules, and emotional dysregulation.
     • Family-Based Treatment (FBT) or Interpersonal Psychotherapy (IPT).
   • Pharmacotherapy:
     • Selective Serotonin Reuptake Inhibitors (SSRIs): Fluoxetine (starting at 10–20 mg/day, titrating up to 60 mg/day) or Sertraline (starting at 25–50 mg/day, up to 150–200 mg/day) to reduce binge frequency and manage co-occurring depression/anxiety.
     • Lisdexamfetamine dimesylate: FDA-approved for moderate-to-severe BED in adults; used selectively under specialist supervision in older adolescents (starting at 30 mg/day, titrating up to 50–70 mg/day).
   • Nutritional & Lifestyle Intervention: Structured meal planning (avoiding prolonged skipping of meals which triggers binging), multidisciplinary lifestyle and metabolic monitoring without overly restrictive diets.

1. Clinical Diagnosis:
   • Cyanotic Breath-Holding Spell (BHS) with reflex anoxic seizure (hypoxic convulsion / syncopal convulsion).
2. Differential Diagnoses:
   • Epileptic seizures (infantile epileptic spasms, focal or generalized tonic-clonic seizures).
   • Cardiac arrhythmias / Long QT Syndrome (LQTS).
   • Vasovagal syncope / Orthostatic syncope.
   • Gastroesophageal reflux with reflex laryngospasm (Sandifer syndrome).
   • Congenital Central Hypoventilation Syndrome (CCHS).
3. Pathophysiology & Iron Deficiency:
   • Breath-holding spells involve involuntary dysregulation of the autonomic nervous system. Vigorous crying induces severe hyperventilation and hypocapnia, leading to cerebral vasoconstriction. Prolonged expiratory apnea against a closed glottis increases intrathoracic pressure, impeding venous return and cardiac output, resulting in cerebral hypoxia that triggers loss of consciousness and brainstem-mediated reflex tonic-clonic motor activity.
   • Iron is an essential cofactor for tyrosine hydroxylase and monoamine oxidase, key enzymes governing catecholamine synthesis and dopamine receptor functioning in the central nervous system. Iron deficiency impairs central autonomic regulation and brainstem respiratory network responsiveness, decreasing the threshold for prolonged vagal discharge, expiratory apnea, and cerebral hypoxia during emotional stress.
4. Investigation & Management:
   • Essential Investigation: Complete Blood Count (CBC) with red cell indices (MCV, MCH, RDW) and Serum Ferritin level (to detect overt or latent iron deficiency). A baseline 12-lead Electrocardiogram (ECG) to exclude prolonged QTc interval.
   • Reassurance: Parent education regarding the involuntary and benign nature of the spells, highlighting the absence of long-term neurological sequelae or risk of epilepsy.
   • Definitive Medical Therapy:
     • Elemental Iron:
       $$ > \text{Dose} = \mathbf{3\text{ to }6\text{ mg/kg/day}}\text{ orally in 2 to 3 divided doses} > $$
     • Duration: Administer for 3 months (even if baseline hemoglobin is normal, as iron therapy markedly reduces spell frequency and severity in both anemic and non-anemic iron-deficient children).

1. Primary Diagnosis:
   • Generalized Anxiety Disorder (GAD).
2. Medical Mimics / Organic Differential Diagnoses:
   • Hyperthyroidism (Thyrotoxicosis).
   • Pheochromocytoma / Functional Paraganglioma (catecholamine hypersecretion).
   • Cardiac arrhythmias (e.g., Paroxysmal Supraventricular Tachycardia).
   • Poorly controlled nocturnal bronchial asthma.
   • Autoimmune encephalitis / Neuropsychiatric Systemic Lupus Erythematosus (SLE).
   • Substance/caffeine toxicity or adverse medication effect (e.g., beta-agonists, stimulants).
3. Validated Pediatric Anxiety Rating Scales:
   • Screen for Child Anxiety Related Disorders (SCARED).
   • Pediatric Anxiety Rating Scale (PARS).
   • Generalized Anxiety Disorder 7-item scale (GAD-7) / Spence Children's Anxiety Scale (SCAS).
4. Multimodal Management Strategy:
   • First-Line Psychotherapy:
     • Individual Cognitive Behavioral Therapy (CBT), specifically manualized pediatric anxiety protocols (e.g., the "Coping Cat" program), incorporating psychoeducation, somatic relaxation training (diaphragmatic breathing, progressive muscle relaxation), cognitive restructuring, and graded exposure therapy.
   • First-Line Pharmacotherapy:
     • Selective Serotonin Reuptake Inhibitor (SSRI): Sertraline or Escitalopram.
     • Sertraline Dosing:
       • Starting dose: 25 mg orally once daily in the morning (or 12.5 mg/day for the first week in highly sensitive children).
       • Titration: Increase by 25 mg every 1 to 2 weeks based on tolerability and clinical response to a target therapeutic dose of 50 to 100 mg/day orally (maximum dose: 200 mg/day).
     • Maintain treatment for at least 12 months after achieving complete symptom remission before considering gradual tapering.

1. Diagnosis: Oppositional Defiant Disorder (ODD).
2. DSM-5 Symptom Clusters:
   • Angry / Irritable Mood: Often loses temper; easily annoyed or touchy; frequently angry and resentful.
   • Argumentative / Defiant Behavior: Often argues with authority figures/adults; actively defies or refuses to comply with rules/requests; deliberately annoys others; blames others for his/her mistakes or misbehavior.
   • Vindictiveness: Has been spiteful or vindictive at least twice within the past 6 months.
3. DSM-5 Severity Classification:
   • Mild: Symptoms are confined to only one setting (e.g., at home, at school, or with peers).
   • Moderate: Symptoms are present in at least two settings.
   • Severe: Symptoms are present in three or more settings.
4. Distinction from Conduct Disorder (CD):
   • Absence of aggression toward people or animals (e.g., physical cruelty, fighting with weapons, forced sexual activity).
   • Absence of deliberate destruction of property (e.g., fire-setting, vandalism).
   • Absence of deceitfulness, theft, or serious violations of societal rules (e.g., running away overnight, chronic truancy before age 13).
   • Presence of emotional dysregulation (angry/irritable mood), which is a cardinal feature of ODD but not a prerequisite for CD.
5. Management Strategy:
   • First-line Psychosocial Intervention: Parent Management Training (PMT) or Parent-Child Interaction Therapy (PCIT) to teach positive reinforcement, consistent discipline, and behavior modification techniques; school-based behavioral support.
   • Role of Pharmacotherapy: Medications are not primary treatment for ODD itself. Indicated only for comorbid conditions (e.g., Stimulants like Methylphenidate or Atomoxetine if comorbid Attention-Deficit/Hyperactivity Disorder is present) or atypical antipsychotics (e.g., Risperidone 0.25–0.5 mg/day) for refractory severe aggression.

1. ADHD Pharmacotherapy:
   • Class & Prototype: Psychostimulant; Methylphenidate (immediate-release or extended-release).
   • Starting Dose: 0.3 mg/kg/day (or 5 mg once to twice daily), titrated weekly by 5–10 mg/day to a maximum of 1.0 mg/kg/day (maximum 60 mg/day).
   • Mechanism of Action: Central dopamine and norepinephrine reuptake inhibitor (blocks DAT and NET transporters in the prefrontal cortex).
2. Autism Spectrum Disorder (Irritability / Aggression):
   • Risperidone: Approved down to 5 years of age (starting dose: 0.25 mg/day for <20 kg; 0.5 mg/day for ≥20 kg).
   • Aripiprazole: Approved down to 6 years of age (starting dose: 2 mg/day, titrated up to 5–10 mg/day).
3. Major Depressive Disorder:
   • Drug & Class: Fluoxetine (Selective Serotonin Reuptake Inhibitor [SSRI]).
   • Starting Dose: 10 mg/day orally, titrated after 1–2 weeks to 20 mg/day.
   • FDA Lower Age Limit: Approved down to 8 years of age (Escitalopram is approved for ≥12 years).
4. Nocturnal Enuresis Pharmacotherapy:
   • Drug & Formulation: Desmopressin acetate (DDAVP); oral tablet or oral lyophilisate (melt).
   • Starting Dose: 0.2 mg orally at bedtime (tablet) or 120 mcg sublingually (melt), titrated up to 0.4 mg tablet or 240 mcg melt.
   • Safety Advisory: Strict fluid restriction starting 1 hour before administration until 8 hours post-dose to prevent water intoxication, dilutional hyponatremia, and hyponatremic seizures.
5. Pediatric Schizophrenia:
   • Second-Generation (Atypical): Risperidone (starting dose 0.5 mg/day) or Aripiprazole (starting dose 2 mg/day) or Olanzapine (starting dose 2.5 mg/day).
   • First-Generation (Typical): Haloperidol (0.05 mg/kg/day) or Chlorpromazine (0.5–1 mg/kg/dose every 6–8 hours).

1. Precise Diagnosis: Primary Monosymptomatic Nocturnal Enuresis (PMNE).
   • Primary: Never achieved nocturnal continence for at least 6 consecutive months.
   • Monosymptomatic: Involuntary voiding during sleep in a child $\ge 5\text{ years}$ of age without daytime lower urinary tract symptoms (LUTS).
2. Pathophysiological Triad:
   • Nocturnal Polyuria: Absence or blunting of the normal circadian nighttime surge of endogenous Antidiuretic Hormone (Arginine Vasopressin [AVP]), leading to urine production exceeding nocturnal bladder capacity.
   • Nocturnal Detrusor Overactivity / Reduced Nocturnal Bladder Capacity: Involuntary uninhibited detrusor contractions during sleep.
   • Arousal Failure / High Sleep Arousal Threshold: Inability of the central nervous system to awaken from deep sleep in response to bladder fullness or uninhibited contractions.
3. First-Line Conditioning Therapy:
   • Modality: Enuresis Alarm therapy (moisture-sensor alarm attached to underwear).
   • Duration & Endpoint: Minimum continuous treatment for 8 to 12 weeks; continued until 14 consecutive dry nights are achieved before gradual discontinuation.
4. Pharmacotherapy:
   • Medication: Desmopressin (oral tablet or oral lyophilisate/melt).
   • Starting Dose: 0.2 mg oral tablet (or 120 mcg oral lyophilisate) administered 1 hour prior to sleep; can be titrated to 0.4 mg tablet (or 240 mcg melt) if partial response.
   • Fluid Advisory: Fluid intake must be restricted to $\le 200\text{ mL}$ (1 cup) from 1 hour before dose administration until the following morning (at least 8 hours post-dose) to avoid life-threatening dilutional hyponatremia.

graph TD
    A[Child ≥5 years with Bed-Wetting] --> B{Daytime LUTS, urgency, or encopresis?}
    B -- Yes --> C[Non-Monosymptomatic Nocturnal Enuresis]
    C --> D[Urological workup: Renal USG, VCUG, Uroflowmetry]
    B -- No --> E[Monosymptomatic Nocturnal Enuresis]
    E --> F{Dry for >6 months previously?}
    F -- Yes --> G[Secondary PMNE: Screen for psychosocial stressors, T1DM, OSA]
    F -- No --> H[Primary Monosymptomatic Nocturnal Enuresis]
    H --> I[First-line: Enuresis Alarm]
    H --> J[Rapid/Short-term relief: Desmopressin + Fluid Restriction]

1. Diagnosis & DSM-5 Category:
   • Diagnosis: Psychogenic Non-Epileptic Seizures (PNES) / Functional Seizures.
   • DSM-5 Categorization: Functional Neurological Symptom Disorder (Conversion Disorder).
2. Distinguishing Semiological Features:
   • Eye Signs: Eyes tightly closed with active resistance to eyelid opening and upward deviation of globes (Bell's phenomenon); in GTCS, eyes are typically open, fixed, or upwardly deviated.
   • Motor Manifestations: Asynchronous, out-of-phase limb movements, pelvic thrusting, and side-to-side head movements ("no-no" head thrashing); in GTCS, movements are synchronous, stereotypic, and in-phase.
   • Duration & Pattern: Prolonged waxing and waning duration (>15–30 minutes) without physiological compromise; GTCS typically lasts 1 to 2 minutes with rhythmic decrescendo frequency.
   • Postictal State: Rapid recovery of alert cognitive baseline without stertorous breathing, prolonged postictal coma, or severe confusion; lack of lateral tongue biting.
3. Gold Standard Diagnostic Test:
   • Continuous Video-Electroencephalography (Video-EEG) Monitoring: Capturing a typical clinical event that demonstrates the absence of paroxysmal epileptiform discharges before, during, and immediately after the event, with preservation of normal background alpha rhythm during apparent unresponsiveness.
4. Communication & Management Principles:
   • Transparent Positive Diagnosis: Present the diagnosis clearly and empathetically as a real, distressing condition (functional neurological disorder) without implying the patient is "faking" or "putting on a show."
   • Avoid Iatrogenic Harm: Taper and discontinue unnecessary anti-seizure medications (ASMs) to prevent drug toxicity.
   • Identify Psychosocial Stressors: Explore underlying stressors (academic pressure, bullying, domestic discord, adverse childhood experiences).
   • Definitive Treatment: Cognitive Behavioral Therapy (CBT) focused on symptom management, stress appraisal, and adaptive coping mechanisms; psychiatric management of comorbid anxiety or depression.

1. Diagnosis: Social Anxiety Disorder (Social Phobia).
2. DSM-5 Diagnostic Criteria:
   • Marked fear or anxiety about one or more social situations in which the individual is exposed to possible scrutiny by others (in children, the anxiety must occur in peer settings and not just during interactions with adults).
   • The individual fears that they will act in a way or show anxiety symptoms that will be negatively evaluated (humiliated, embarrassed, rejected).
   • The social situations almost always provoke fear or anxiety (in children, may be expressed by crying, tantrums, clinging, or failing to speak).
   • The social situations are actively avoided or endured with intense fear or anxiety.
   • The fear, anxiety, or avoidance is persistent, typically lasting for $\ge 6\text{ months}$, and causes clinically significant impairment in social, academic, or occupational functioning.
3. Differential Diagnoses:
   • Generalized Anxiety Disorder (GAD): Worry is pervasive and multisystemic across multiple everyday domains (health, finances, family safety), not restricted to social scrutiny.
   • Panic Disorder: Recurrent unexpected panic attacks that occur without an identifiable social trigger.
   • Selective Mutism: Complete failure to speak in specific social situations despite speaking in other situations, without the pervasive fear of negative peer scrutiny seen in older children.
   • Avoidant Personality Disorder / Major Depressive Disorder: Social withdrawal driven by low energy/anhedonia or pervasive feelings of inadequacy.
4. Multimodal Management:
   • First-line Psychotherapy: Cognitive Behavioral Therapy (CBT) with individual or group-based systematic graduated exposure therapy, cognitive restructuring, and social skills training.
   • First-line Pharmacotherapy: Selective Serotonin Reuptake Inhibitor (SSRI).
     • Sertraline: Starting dose 25 mg orally once daily, titrating after 1 to 2 weeks to 50 mg daily (effective range: 50–200 mg/day).
     • Alternative: Fluoxetine 10 mg orally once daily, titrated to 20 mg daily.
   • Duration: Pharmacotherapy should be continued for at least 12 months following symptomatic remission before attempting a slow, structured taper.

1. Definitive Diagnosis:
   • Specific Learning Disorder (SLD) with impairment in reading (dyslexia) and impairment in written expression (dysgraphia).
2. Associated Comorbidities:
   • Attention-Deficit/Hyperactivity Disorder (ADHD; most common, occurring in 30–40% of cases)
   • Developmental Coordination Disorder (dyspraxia)
   • Developmental Speech and Language Disorders (e.g., expressive language disorder)
   • Internalizing disorders: Anxiety disorders and Major Depressive Disorder (secondary to chronic academic frustration)
3. Indian Diagnostic Assessment Tools:
   • NIMHANS Index for Specific Learning Disabilities (Levels I and II)
   • Dyslexia Assessment for Languages of India (DALI)
   • Grade Level Assessment Device (GLAD)
4. RPwD Act Provisions / Examination Concessions:
   • Compensatory extra time (minimum 20 minutes per hour of examination)
   • Provision of an amanuensis (scribe) or reader
   • Exemption from a third language or option to drop an elective language in secondary board exams
   • Exemption from penalization for spelling, punctuation, and grammatical errors in non-language subjects
   • Permission to use assistive technology (calculators, word processors, or screen readers)
5. Core Non-Pharmacological Management:
   • Formulation of an Individualized Education Program (IEP).
   • Remedial education utilizing Multisensory Structured Language (MSL) therapy (e.g., Orton-Gillingham approach) focusing on phonological awareness, sound-symbol association, syllable instruction, morphology, and syntax.

1. Primary Diagnosis:
   • Tourette Disorder (Tourette Syndrome).
2. DSM-5 Diagnostic Criteria:
   • Presence of both multiple motor tics and one or more vocal tics at some time during the illness (not necessarily concurrently).
   • Tics persist for more than 1 year since the first tic onset.
   • Onset occurs prior to age 18 years.
   • The disturbance is not attributable to the physiological effects of a substance (e.g., cocaine, stimulants) or another medical condition (e.g., Huntington disease, postviral encephalitis).
3. Differential Diagnoses:
   • Transient (Provisional) Tic Disorder (duration $<1$ year)
   • Stereotypic Movement Disorder (motor stereotypies: rhythmic, fixed, bilateral, early onset, non-suppressible without premonitory urge)
   • Compulsions in Obsessive-Compulsive Disorder (complex, goal-directed rituals performed to neutralize an obsession)
   • Sydenham chorea / PANDAS
   • Drug-induced akathisia or tardive dyskinesia
   • Wilson disease
4. Key Psychiatric Comorbidities:
   • Attention-Deficit/Hyperactivity Disorder (ADHD; present in 50–60%)
   • Obsessive-Compulsive Disorder (OCD; present in 30–50%)
5. First-Line Non-Pharmacological Therapy:
   • Comprehensive Behavioral Intervention for Tics (CBIT), which incorporates Habit Reversal Training (HRT; awareness training and competing response training) and exposure with response prevention.
6. Pharmacotherapeutic Agents & Dosing:
   • Clonidine (Alpha-2 adrenergic agonist, preferred initial agent):
     • Dose: $0.025\text{ to }0.05\text{ mg/day}$ orally at bedtime; titrate by $0.025\text{ to }0.05\text{ mg}$ every 5–7 days to a target maintenance of $0.1\text{ to }0.3\text{ mg/day}$ divided 2 to 3 times daily.
   • Aripiprazole (Atypical antipsychotic, FDA approved):
     • Dose: $1\text{ to }2\text{ mg/day}$ orally once daily; titrate slowly by $1\text{ to }2\text{ mg/day}$ every 1–2 weeks to an effective range of $2.5\text{ to }10\text{ mg/day}$ (max $15\text{ mg/day}$).

1. Diagnosis & Causative Agent:
   • Chemotherapy-Induced Peripheral Neuropathy (CIPN) / Toxic sensorimotor polyneuropathy.
   • Causative agent: Vincristine.
2. Neurological Sensory Phenomenon:
   • Allodynia (mechanical/tactile allodynia: pain provoked by an innocuous stimulus that does not normally cause pain).
3. Mechanism of Neurotoxicity:
   • Vincristine binds to $\beta$-tubulin subunits, inhibiting microtubule polymerization and mitotic spindle formation.
   • In peripheral neurons, this disrupts microtubule-dependent axonal transport (both anterograde and retrograde fast and slow axonal transport), leading to distal axonal dying-back neuropathy predominantly affecting long, large-diameter sensory and motor nerve fibers.
4. Maximum Single-Dose Cap:
   • Absolute maximum cap of $2.0\text{ mg}$ per single dose, regardless of the calculated body surface area (BSA).
5. Symptomatic Pharmacotherapy:
   • Gabapentin:
     • Initial dose: $5\text{ to }10\text{ mg/kg/day}$ orally divided every 8 hours.
     • Titrate over 3–5 days to $20\text{ to }30\text{ mg/kg/day}$ orally in 3 divided doses (maximum $1800\text{ to }2400\text{ mg/day}$).
   • Pregabalin:
     • Initial dose: $2\text{ to }3\text{ mg/kg/day}$ orally divided every 12 hours.
     • Titrate up to $5\text{ to }6\text{ mg/kg/day}$ orally divided in 2 doses (maximum $300\text{ mg/day}$).
6. Oncological Protocol Modification:
   • Withhold (omit) vincristine temporarily until motor deficits resolve or improve to mild Grade 1 neuropathy.
   • Upon resumption of chemotherapy, reduce the vincristine dose by 50% (e.g., resume at $0.75\text{ mg/m}^2/\text{dose}$, retaining the cap), or omit entirely if severe disabling paresis persists.